Neurocrine reports Q2 non-GAAP EPS $1.65, consensus $1.50

Reports Q2 revenue $682M, consensus $653.87M. “As we begin our transition into a new chapter of growth and diversification for Neurocrine (NBIX), we’re pleased with our Q2 commercial performance across tardive dyskinesia, Huntington’s chorea, and now, classic congenital adrenal hyperplasia,” said CEO Kyle Gano. “Although still early in our launch, the demand for CRENESSITY remains robust, underscoring the significant unmet need for a novel treatment option for patients with CAH. With revenue contributions from both INGREZZA and CRENESSITY along with our strong balance sheet, we are well-positioned to advance and expand our neuropsychiatry pipeline, including our ongoing registrational programs in major depressive disorder with osavampator and in schizophrenia with NBI-‘568, our selective M4 muscarinic agonist.”